)
Visual
test
Curasight
Curasight (CURAS) investor relations material
Curasight Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary1 Dec, 2025
Executive summary
Advanced clinical and strategic progress in precision diagnostics and targeted radionuclide therapy for cancer, with a focus on brain and prostate cancer.
Initiated Phase 1 trial for uTREAT® in brain cancer after receiving all necessary approvals; first patient dosing and initial biodistribution data expected by year-end.
Expanded recruitment in the uTRACE® Phase II prostate cancer trial, with all European sites now active.
Strengthened intellectual property with a new US patent for uTRACE®, extending protection to 2035.
Financial highlights
Q3 2025 gross loss: KDKK -12,076 (Q3 2024: KDKK -6,135); operating loss: KDKK -13,545 (Q3 2024: KDKK -8,099); loss before tax: KDKK -14,262 (Q3 2024: KDKK -8,523); loss for the period: KDKK -12,887 (Q3 2024: KDKK -7,148).
Q1–Q3 2025 gross loss: KDKK -34,475 (Q1–Q3 2024: KDKK -22,521); operating loss: KDKK -38,765 (Q1–Q3 2024: KDKK -28,443); loss before tax: KDKK -41,420 (Q1–Q3 2024: KDKK -30,002); loss for the period: KDKK -37,295 (Q1–Q3 2024: KDKK -25,877).
Earnings per share Q3 2025: DKK -0.28 (Q3 2024: DKK -0.35); Q1–Q3 2025: DKK -0.81 (Q1–Q3 2024: DKK -1.25).
Cash at September 30, 2025: KDKK 15,898 (September 30, 2024: KDKK 7,938).
Equity ratio at September 30, 2025: 52.6% (September 30, 2024: 51.6%).
Outlook and guidance
Focus on disciplined execution across all programs, with first patient dosing in uTREAT® Phase 1 brain cancer trial expected in H2 2025.
Plan to initiate a Phase II basket trial in 2026, covering five cancer indications using the theranostic platform.
Ongoing business development discussions with major pharma companies for UTRACE® and uTREAT® partnerships.
Cash runway given current burn rate
Rationale for uTREAT single indication then basket study?
Priorities for new uTRACE/uTREAT partnerships?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 6 FebWASH
Q4 2025 net income up 48%, adjusted EPS up 41%, AUA $7.8B, dividend yield 7.58%. - 6 FebJ
Strong growth, digital innovation, and margin expansion drive robust multi-year financial outlook. - 6 Feb004020
Operating profit rose on cost savings and high-value sales, with major US expansion underway. - 6 FebJOUT
Net sales up 31%, gross margin at 36.6%, and net loss narrowed to $3.3 million. - 6 FebPECO
Record 2025 occupancy and 7% Core FFO growth; 2026 targets 5.5% FFO growth and strong acquisitions. - 6 FebPROV
Q2 FY2026 net income rose 65% year-over-year, with higher margins and strong credit quality. - 6 FebNVDA
AI-driven digital twins and accelerated computing are set to revolutionize industrial design and manufacturing. - 6 FebCDP
2025 FFO/share rose 5.8% to $2.72, with strong leasing and investment; 2026 guidance signals more growth. - 6 FebCRI
Q1 2025 saw record revenue, a return to profit, and major new contracts in space technology. - 6 FebCRINet loss widened to 7.5m PLN in H1 2024 as revenue fell and R&D costs remained high.
Next Curasight earnings date
Q4 202527 Feb, 2026
Curasight
Next Curasight earnings date
Q4 202527 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Curasight is a clinical stage biopharmaceutical company dedicated to developing uPAR Theranostics for the early detection, diagnosis and treatment of cancer. The company's mission is to make a global impact by harnessing imaging technology that improves diagnosis and correlates to improved long-term patient outcome.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage